TransEnterix (NYSEAMERICAN:TRXC) Shares Gap Up to $1.05

Shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) gapped up before the market opened on Monday . The stock had previously closed at $1.18, but opened at $1.05. TransEnterix shares last traded at $1.03, with a volume of 20,306 shares.

A number of equities research analysts recently weighed in on the stock. Piper Jaffray Companies assumed coverage on shares of TransEnterix in a report on Wednesday, May 22nd. They set a “neutral” rating and a $1.60 price objective for the company. BTIG Research upgraded shares of TransEnterix from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, May 14th. Royal Bank of Canada lowered shares of TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price target for the company. in a report on Thursday. Finally, Zacks Investment Research lowered shares of TransEnterix from a “hold” rating to a “sell” rating in a report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $2.62.

TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $3.64 million for the quarter, compared to analyst estimates of $5.13 million.

A number of hedge funds and other institutional investors have recently made changes to their positions in TRXC. Legal & General Group Plc raised its position in TransEnterix by 16.6% during the fourth quarter. Legal & General Group Plc now owns 28,558 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 4,059 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in TransEnterix by 13.2% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 65,706 shares of the medical instruments supplier’s stock worth $156,000 after acquiring an additional 7,644 shares during the period. Oppenheimer & Co. Inc. raised its position in TransEnterix by 45.5% during the first quarter. Oppenheimer & Co. Inc. now owns 32,000 shares of the medical instruments supplier’s stock worth $76,000 after acquiring an additional 10,000 shares during the period. Sheets Smith Wealth Management raised its position in TransEnterix by 100.0% during the first quarter. Sheets Smith Wealth Management now owns 20,000 shares of the medical instruments supplier’s stock worth $48,000 after acquiring an additional 10,000 shares during the period. Finally, Northern Trust Corp raised its position in TransEnterix by 0.6% during the fourth quarter. Northern Trust Corp now owns 1,968,519 shares of the medical instruments supplier’s stock worth $4,448,000 after acquiring an additional 10,930 shares during the period.

TransEnterix Company Profile (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Recommended Story: Special Dividends

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.